Phase II Study of the Efficacy and Safety of Lenalidomide in Adult Subjects With Intermediate-2-or Higt Risk Myelodysplastic Syndrome(MDS) Associated With a Deletion (DEL) 5q [31]
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 29 Sep 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2007-000246-13)
- 12 Mar 2007 Biomarkers information updated
- 15 Feb 2007 New trial record.